NCT04888468View on ClinicalTrials.gov

Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

June 29, 2021

Study Completion Date

September 1, 2021

Conditions
Acute Lymphoblastic LeukemiaRelapsed Pediatric ALLRefractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

pCAR-19B cells

Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

Unknown

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY

NCT04888468 - Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Biotech Hunter | Biotech Hunter